Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Mirum Pharmaceuticals granted Chief Medical Officer Rob Myers 40,000 non-qualified stock options and 25,000 restricted stock units on October 9, 2026. Another 18 new employees received 18,663 non-qualified stock options and 24,687 restricted stock units under the 2020 Inducement Plan. Stock options vest over four years
For best results when printing this announcement, please click on link below: Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on October 9, 2026, the Compensation Committee of Mirum’s Bo
Mirum Pharmaceuticals granted Chief Medical Officer Robert Paul Myers 40,000 employee stock options on Oct. 9, 2026. Myers also received 25,000 restricted stock units on the same date. * The options expire on Oct. 8, 2036. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial